Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
IRBM has signed a service and development agreement with the University of Texas MD Anderson Cancer Center to develop monoclonal antibodies targeting a novel immune checkpoint. The two will combine their discovery technologies to identify and validate lead antibodies through preclinical proof of concept studies. IRBM will use its phage display antibody libraries and immuno-oncology capabilities to generate and optimize fully human antibody candidates against the undisclosed target.
This article has been sent to the following recipient: